Docket No. GJE-7147 Serial No. 10/517,881

In the Specification

Please amend the paragraph on page 2, lines 13-23 as follows:

As used herein, "nefopam" refers to a compound of formula 1

and salts, e.g. the hydrochloride, metabolites and prodrugs thereof, as well as the (+) and (-) cnantiomers which are as far as possible optically pure. (+)- Nefopam may be preferred preferred, for reduced side-effects caused by interaction.

Please amend the paragraph on page 3, lines 16-25 as follows:

Nefopam may be used according to the invention when the patient is also being given another anti-emetic agent. Such agents include phenothiazines, 5HT3 receptor antagonists, dopamine antagonists, anti-cholinergic agents, anti-histamines, histamine analogues, cannabinoids, corticosteroids, GABA receptor antagonists, NK1 receptor antagonists, and α_2 and α_3 adrenoceptor antagonists. Specific examples of these types of compounds are cyclizine, dolasetron, granisetron, ondansetron, tropisetron, nabilone, scopolenine, cinnerizinc, promethazine, betahistine, dexamethasomedexamethasone, methylprednisolone, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, thiethylperazine, droperidol, domperidone and haloperidol.